Cellyan Biotechnology Co., Ltd (HKPD) Fair Value 2026

HKPD · Medical Distribution ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

2.5 /10

32 fundamental signals · 0 models active

Value Trap Risk

SAFE (0/100)

Quick Summary — As of 2026-08-28, Cellyan Biotechnology Co., Ltd (HKPD) trades at $0.35. QOC: 2.5/10. Value Trap Risk: 0/100 (SAFE). 0/13 models active.

Key Facts

Ticker
HKPD
Price
$0.35
Quality Score
2.5/10
Value Trap Risk
0/100
Models Active
0/13
Last Updated
Strength: 0 independent models provide multi-angle coverage
Risk: Below-average Quality Score of 2.5/10 signals weak fundamentals

What Fair Value Does Each Model Give HKPD?

0 Intrinsic Value Models vs. Current Price ($0.35)

Core Models (Unlocked)
Model Fair Value Upside

All Models Active

All 0 models are displayed above.

What Is Cellyan Biotechnology Co., Ltd (HKPD) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Cellyan Biotechnology Co., Ltd currently lacks sufficient data across our 13-model framework. As more financial data is processed from SEC filings, our models will generate intrinsic value estimates.

What Do the Models Say About HKPD?

0 of 13 models are currently active for HKPD. See which stocks rank higher →

How Does HKPD Rank in Medical Distribution?

Among 13 Medical Distribution stocks, HKPD ranks #12 by Quality of Company score. CirclFi's QOC score of 2.5/10 evaluates 32 fundamental signals. A score of 2.5 signals below-average fundamentals.

Cellyan Biotechnology Co., Ltd operates in a competitive landscape where fundamental quality metrics are key differentiators for long-term value creation.

Is HKPD a Value Trap?

CirclFi's Value Trap algorithm assigns HKPD a score of 0/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

0 of 13 models are active for Cellyan Biotechnology Co., Ltd. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Cellyan Biotechnology Co., Ltd's fundamental quality profile registers 2.5/10. This concerning score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every HKPD valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Cellyan Biotechnology Co., Ltd Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Distribution Stocks Should You Also Analyze?

8 related Medical Distribution stocks with 13-model coverage

MEDSDataMEDS AI, Inc.QOC 4.3AHGAkso Health GroupQOC 2.2COSMCosmos Health Inc.QOC 4.5MCKMcKesson CorporationQOC 8.7SNYRSynergy CHC Corp.QOC 4.6CORCencora, Inc.QOC 8.3YI111, Inc.QOC 6.8VNOVVNOVQOC 5.6

Read investment analysis: MEDS · AHG · COSM · MCK · SNYR · COR · YI · VNOV

Which Other Stocks Have a Similar Quality Score to HKPD?

7 companies across all industries closest to HKPD’s Quality of Company score of 2.5/10.

XNETXunlei LimitedQOC 2.5TATTTAT Technologies Ltd.QOC 2.5GLMDGalmed Pharmaceuticals Ltd.QOC 2.5MTCMMTec, Inc.QOC 2.5CXCEMEX, S.A.B. de C.V.QOC 2.5SYNXSilynxcom Ltd.QOC 2.5NVDANVIDIA CorporationQOC 10.0

Read investment analysis: XNET · TATT · GLMD · MTC · CX · SYNX · NVDA

What Else Do Investors Ask About Cellyan Biotechnology Co., Ltd’s Valuation?

What is Cellyan Biotechnology Co., Ltd's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Cellyan Biotechnology Co., Ltd (HKPD). The Quality of Company score is 2.5/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is HKPD overvalued or undervalued right now?

At $0.35, 0 of 0 active models suggest HKPD may be undervalued, while 0 indicate potential overvaluation. The assessment depends on which methodology best fits Cellyan Biotechnology Co., Ltd's business model in Medical Distribution.

What does a Quality of Company score of 2.5 mean for HKPD?

Cellyan Biotechnology Co., Ltd's QOC of 2.5/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on HKPD?

CirclFi analyzes HKPD with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 0 of 13 are active for this stock. Read the full methodology →

Is HKPD a value trap in 2026?

Cellyan Biotechnology Co., Ltd's Value Trap score is 0/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Cellyan Biotechnology Co., Ltd (HKPD) a Quality of Company score of 2.5/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/HKPD/ · Methodology
Primary sources for this HKPD valuation
  • Financial statements: Cellyan Biotechnology Co., Ltd 10-K and 10-Q filings on SEC EDGAR (CIK 0002007702) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for HKPD as of ; valuations recomputed .